|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 45/06 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 3728313 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18829861.6 |
| Date of filing the European patent application | 2018-12-21 | |
| (97) | Date of publication of the European application | 2020-10-28 |
| (45) | Date of publication and mention of the grant of the patent | 2023-08-02 |
| (46) | Date of publication of the claims translation | 2023-11-10 |
| (86) | Number | PCT/EP2018/086606 |
| Date | 2018-12-21 |
| (87) | Number | WO 2019/122337 |
| Date | 2019-06-27 |
| (30) | Number | Date | Country code |
| PCT/IB2017/001595 | 2017-12-21 | WO |
| (72) |
VUAGNIAUX, Grégoire , CH
WIEDEMANN, Norbert , CH
GAVILLET, Bruno , FR
SZYLDERGEMAJN ALTMAN, Sergio Adrian , CH
|
| (73) |
Debiopharm International S.A. ,
Forum "après-demain"
Chemin Messidor 5-7, 1006 Lausanne,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Priešvėžinės terapijos derinys su IAP antagonistu ir anti-PD-1 molekulė |
| COMBINATION ANTI CANCER THERAPY WITH AN IAP ANTAGONIST AND AN ANTI PD-1 MOLECULE |
| Payment date | Validity (years) | Amount | |
| 2024-12-03 | 7 | 162.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-09-18 |